Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men

M. Mottolese, G. Bigotti, A. Coli, C. Vitucci, P. G. Natali

Research output: Contribution to journalArticlepeer-review

Abstract

Immunohistochemical (IHC) assays using the monoclonal antibodies (MoAbs) B72.3 and B6.2, recognizing two distinct and independently expressed breast tumor-associated antigens (BTAAs), recently have been shown to significantly improve the accuracy of cytodiagnosis of breast nodules by fine-needle aspiration (FNA). To evaluate whether the same method may be useful diagnostically in distinguishing gynecomastia from breast cancer in men, a retrospective avidin-biotin immunoperoxidase assay study was performed on 50 cases of gynecomastia and 30 cases of breast carcinoma in men, using a panel of five MoAbs known to recognize different BTAAs. The results of this study demonstrated that MoAbs B1.1, HMFG2, and MBr1 displayed a strong reactivity with gynecomastia and carcinoma, but MoAbs B72.3 and B6.2 separated benign and malignant lesions in a high percentage of cases. When used in combination, the latter two reagents reacted with 96% of the carcinomas that were analyzed but labeled only 67% of gynecomastia cases. Thus, the conjoint use of these two reagents may enhance the use of FNA biopsy as a valuable tool in the presurgical diagnosis of breast nodules in men.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume96
Issue number2
Publication statusPublished - 1991

Keywords

  • Breast carcinoma
  • Fine-needle aspiration
  • Gynecomastia
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men'. Together they form a unique fingerprint.

Cite this